Effects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV

In brief

To investigate the effects of food and dose regimen on the antiviral effects of Maraviroc (UK-427,857) in patients with human immunodeficiency virus (HIV)

Key facts

Study ID

NCT00634959

Run by

ViiV Healthcare

People needed

37

Starts

2003-07-01

Expected to finish

2003-12-01

Last updated by the study team

2010-11-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Asymptomatic HIV-1 infected male and female patients
• Weight between 50 and 100kg and within the permitted range for their height
• Patients with virus that targets CCR5 receptor

You may not qualify if…

• Patients with a CD4 count <250 cells/mm3 or HIV viral load <5000 copies/mL
• Patients whose HIV infection has been diagnosed less than 3 months prior to screening, or for who there is evidence of recent seroconversion
• Patients with acquired immunodeficiency syndrome (AIDS) or a previous AIDS diagnosis
• Patients who are taking or have taken antiretroviral drugs in the eight weeks prior to the study screening visit

Where it is running

• Pfizer Investigational Site — Birmingham, Alabama, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Cologne, Germany
• Pfizer Investigational Site — Frankfurt, Germany
• Pfizer Investigational Site — Hamburg, Germany
• Pfizer Investigational Site — London, United Kingdom
• Pfizer Investigational Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.